Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06132503 · ClinicalTrials.gov registry record · Phase 1
Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors
A Phase 1 study of Advanced Solid Tumor and Relapsed or Refractory Lymphomas, sponsored by Lantern Pharma.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 110
- Enrollment target
- 4
- Study locations
NCT06132503: Recruiting Phase 1 study of Advanced Solid Tumor and Relapsed or Refractory Lymphomas, sponsored by Lantern Pharma.
NCT06132503 is a Phase 1 study of Advanced Solid Tumor and Relapsed or Refractory Lymphomas that is actively recruiting participants, run by Lantern Pharma. The registered enrollment target is 110 participants, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (43% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06132503, a Phase 1 study of Advanced Solid Tumor and Relapsed or Refractory Lymphomas, is actively recruiting participants, sponsored by Lantern Pharma.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 110 participants
- Enrollment target
- 4
- Study locations
Study Summary
The goal of this clinical trial is to evaluate the safety and tolerability of escalating doses of LP-284 and to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) in patients with relapsed or refractory (R/R) lymphomas and solid tumors. The secondary objectives are to characterize the pharmacokinetics (PK) of LP-284 and to assess clinical activity of LP-284.
Primary Outcome
Evaluate the safety and tolerability of escalating doses of LP-284 by measuring the incidence and severity of adverse events (AEs) of escalating doses of LP-284 to determine the maximum tolerated dose (MTD) in patients with relapsed or refractory (R/R) lymphomas and solid tumors
Conditions Studied
Interventions
- DRUG LP-284
Study Locations (4)
California
- Cancer and Blood Specialists Clinic - Los Alamitos
Florida
- Florida Cancer Specialists - Lake Mary
Tennessee
- SCRI Oncology Partners - Nashville
Utah
- START Mountain Region - West Valley City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2023-01-03 |
| Est. Completion | 2028-11-30 |
| Phase | Phase 1 |
What NCT06132503 shows while recruiting
NCT06132503 is an interventional study that assigns participants to a tested intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (43% lower).
The record links to 2 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which LP-284 is the first listed.
NCT06132503 reports a single indexed study location in California, Florida, Tennessee.
Frequently Asked Questions
What is clinical trial NCT06132503 about?
NCT06132503 is a clinical study titled "Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors". The goal of this clinical trial is to evaluate the safety and tolerability of escalating doses of LP-284 and to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) in patients with relapsed or refractory (R/R) lymphomas and solid tumors. The secondary objectives are to...
What is the current status of trial NCT06132503?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 110 participants. The study started on 2023-01-03. Estimated completion is 2028-11-30.
What conditions does trial NCT06132503 study?
This clinical trial studies the following conditions: Advanced Solid Tumor, Relapsed or Refractory Lymphomas.
What interventions are being tested in trial NCT06132503?
The interventions under investigation include: LP-284 (DRUG).
Who is sponsoring clinical trial NCT06132503?
This trial is sponsored by Lantern Pharma, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06132503 being conducted?
This trial has 4 study locations across California, Florida, Tennessee, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06132503's enrollment target sits among peer trials
110 109th of 189 higher than 80 of 189 other Advanced Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01530373 · 110 participants · Phase 2
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
- NCT02379377 · 110 participants · Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
- NCT02411773 · 110 participants · Phase 1
Sympatholysis in Chronic Kidney Disease
- NCT03190941 · 110 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI